ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
← catalyst calendarNCT06787144 · readout ≤ 530 d
Sponsored by Enliven Therapeutics (industry) · ELVN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
21estimated
Sites
4
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-23 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- CML (Chronic Myelogenous Leukemia)
- Chronic Phase CML
Intervention
- Drug: ELVN-001
Primary outcomes
what the primary-completion date above is the date OFPart 1: Incidence of dose limiting toxicities
measured 28 days
Part 1: Incidence of adverse events (AEs)
measured Up to 28 days
Part 1: Incidence of clinically significant laboratory abnormalities
measured Up to 28 days
Part 1: Incidence of clinically significant ECG abnormalities
measured Up to 28 days
Part 2: Incidence of adverse events
measured Up to 3 years
Part 2: Incidence of clinically significant laboratory abnormalities
measured Up to 3 years
Part 2: Incidence of clinically significant ECG abnormalities
measured Up to 3 years
Permalink · ELVN's whole pipeline · Catalyst calendar · Every registered study · What changed